Onco Actu du 30 mai 2017

	4.1 Dép., diag. & prono. - Prostate
Medicare Coverage of Prolaris® Test Expands with the Addition of Men Diagnosed with Favorable Intermediate Risk Prostate Cancer [Myriad] Prolaris Now Accessible to 70 percent of Medicare Patients with Prostate Cancer.
	5.12 Immunothérapies
A Brain Tumor Kept at Bay by Immunotherapy [Dana-Farber Cancer Institute] “Patients with brain tumors who benefit from immunotherapy drugs are a small percentage of the population that’s treated – maybe 5 to 10 percent,” says David Reardon, MD, Wall’s physician and clinical director of the Center for Neuro-Oncology at Dana-Farber.
	5.12.2 Immunothérapies - CAR-T
Celyad obtains additional US patent for cancer treatment based on TCR-deficient allogeneic CAR-T cells [Celyad] This new patent claims specifically methods of treating cancer patients with allogeneic TCR-deficient CAR-T immunotherapies.
	5.3 Traitements - FDA, EMA, NICE...
NICE Terminates Technology Appraisal for Afatinib in Advanced Squamous NSCLC After Platinum-based Chemotherapy [ESMO] NICE will review this decision if the company decides that it wants to make a full submission.
	5.4 Traitements - Economie
A Look at Major Drug-Pricing Proposals [NY Times] Several bills that seek to tackle the high cost of prescription drugs are moving through Congress, and the Trump administration has also signaled that it may take action. Here’s a list of the major drug-pricing proposals under consideration.
Drug Lobbyists’ Battle Cry Over Prices: Blame the Others [NY Times] Its trade group, the Pharmaceutical Research and Manufacturers of America, or PhRMA, was so concerned about its vulnerability this year that it increased its annual dues by 50 percent — generating an extra $100 million to flood social media, television stations, as well as newspapers and magazines with advertising that reminds consumers of the industry’s role in helping to save lives.
	6. Lutte contre les cancers
Amid Budget Concerns, NIH Preps Beta Test for Precision Medicine Plan [Xconomy] Originally called the Precision Medicine Initiative, or PMI, its name was recently changed to “All of Us.” Collins, speaking at Duke University during the Precision Medicine World Conference, said the name change better conveys that the medical questions the initiative is trying to answer will help everyone.
The trauma of a breast cancer diagnosis can have cognitive effects [Reuters] "Studies with spectacular findings are relatively easy to publish, even if they are small and their methods questionable, and of course all researchers need to publish. Journalists and the public should therefore be particularly wary of small studies with large and unambiguous effects.”
	6.10 Politiques
Report reveals benefits of EU-UK medical research partnerships [Cancer Research UK] A number of experts from across Europe were interviewed for the report. Many highlighted the UK’s ability to conduct translational research to discover new treatments and devices that can benefit patients across Europe.
	6.10.1 Politiques (USA)
Trump tweet on health care spending at odds with White House budget [STAT] It’s unclear what, if anything, Trump’s tweet means for his administration’s spending priorities. The White House declined to elaborate.
	6.4 Médico-éco
High-Priced Drugs Raise Costs For Seniors in Medicare Part D [Wall Street Journal] Spending on Medicare’s drug program has soared, growing faster than all other areas of Medicare.
	6.6 Publications
Science Needs a Solution for the Temptation of Positive Results [NY Times] Science has a reproducibility problem. And the ramifications are widespread.
	6.7 DMP, Big Data & applis
Is Big Data Eclipsing the Role of Randomized Controlled Trials? [ISPOR] Renowned Researchers and Health Policy Experts Weigh In.
Software simplified [Nature] Containerization technology takes the hassle out of setting up software and can boost the reproducibility of data-driven research.